Fiche publication
Date publication
juin 2023
Journal
Blood advances
Auteurs
Membres identifiés du Cancéropôle Est :
Dr OJEDA-URIBE Mario
Tous les auteurs :
Fenaux P, Gobbi M, Kropf P, Issa JJ, Roboz GJ, Mayer J, Krauter J, Robak T, Kantarjian HM, Novak J, Jedrzejczak WW, Thomas X, Ojeda-Uribe M, Miyazaki Y, Min YH, Yeh SP, Brandwein JM, Gercheva-Kyuchukova LT, Demeter J, Griffiths EA, Yee KWL, Döhner K, Hao Y, Keer HN, Azab M, Döhner H
Lien Pubmed
Résumé
This phase 3 study evaluated the efficacy and safety of the new hypomethylating agent guadecitabine (n = 408) vs a preselected treatment choice (TC; n = 407) of azacitidine, decitabine, or low-dose cytarabine in patients with acute myeloid leukemia (AML) unfit to receive intensive induction chemotherapy. Half the patients (50%) had poor Eastern Cooperative Oncology Group Performance Status (2-3). Coprimary endpoints were complete remission (19% and 17% of patients for guadecitabine and TC, respectively [stratified P = 0.48]) and overall survival (median survival 7.1 and 8.5 months for guadecitabine and TC, respectively [hazard ratio 0.97; 95% confidence interval 0.83, 1.14; stratified log-rank P = 0.73]). One- and 2-year survival estimates were 37% and 18% for guadecitabine, and 36% and 14% for TC. A large proportion of patients (42%) received <4 cycles of treatment in both arms. In a post hoc analysis of patients who received ≥4 treatment cycles, guadecitabine was associated with longer median survival vs TC (15.6 vs 13.0 months [hazard ratio 0.78; 95% confidence interval 0.64, 0.96; log-rank P = 0.02]). There was no significant difference in the proportions of patients with grade ≥3 adverse events between guadecitabine (92%) and TC (88%); however, grade ≥3 AEs febrile neutropenia, neutropenia, and pneumonia were higher with guadecitabine. In conclusion, there was no significant difference in efficacy between guadecitabine and TC in the overall population. This trial was registered at www.clinicaltrials.gov as #NCT02348489.
Référence
Blood Adv. 2023 06 5;:
